Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?
Santos-Gallego, Carlos G., Garcia-Ropero, Alvaro, Mancini, Donna, Pinney, Sean P., Contreras, Johanna P., Fergus, Icilma, Abascal, Vivian, Moreno, Pedro, Atallah-Lajam, Farah, Tamler, Ronald, Lala, AnJournal:
Cardiovascular Drugs and Therapy
DOI:
10.1007/s10557-018-06850-0
Date:
January, 2019
File:
PDF, 730 KB
2019
File converter
More search results
More benefits 
